I have put in a request to Market Surveillance at the NYSE AMEX to stop trading in Telkonet (TKO) until the company puts out a press release on the results of the vote on Proposal #3 at yesterday’s annual meeting. There is no excuse for not getting this information out immediately, especially with the stock trading down 20% (only three cents) today.

Since Dendreon’s (DNDN) conference call on April 13 to announce that the Provenge Phase III IMPACT clinical trial easily met its primary endpoint of a 22% reduction in deaths versus the placebo group, there have been numerous posts, articles and message board flames on both sides about what happens next. Not one of the seven analysts who published a rating on Dendreon’s stock recommended buying it ahead of the release of the positive results, and not one has raised their rating to buy since the conference call. That’s remarkable, not just because this is the first cancer vaccine that will be approved by the FDA, but because Provenge works the way an effective drug should work with no significant side effects. Just in the small group for which it was approved, it is likely to be a billion-dollar drug in the U.S. alone, as I will show in the model below.

My valuation model explained below shows $1.5 billion dollars in Provenge revenue should equate to about $30 on DNDN stock today. Considering the potential for immediate off-label use in earlier stages of prostate cancer, I think

Read the rest of this entry

Some of you were worried about articles on the web that allege an April 2009 termination of Provenge IMPACT Phase III test. They said that at 304 deaths (just triggered), the FDA automatically ends the test. The implication these articles tried to make was that the 22% target for reductions in deaths was not met.

That implication is false. We knew the trial of 512 men would end when 304 of them died. That was agreed to with the FDA. The surprise was that this happened in time for an April analysis instead of a second half analysis.

But this in no way implies the trial failed. Most likely,

Read the rest of this entry

Maribavir, which VPHM in-licensed from GlaxoSmithKline six years ago, flat-out failed its Phase III trial in CMV infections in stem-cell transplant patients. But Vancocin still is more than a year away from generic competition, maybe two years, and Cinryze is a certain hit, with the sales acceleration starting right now. The near-term value drivers in VPHM always have been

Read the rest of this entry